secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2025-03-18T23:59:59+00:00
Accession:  0000950170-25-041186
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema reports FY2024 net loss $129.5M; cash $434.1M; palazestrant Phase 3 on track
--------------------------------------------------------------------------------

- Net loss Q4 $33.6M, FY $129.5M vs. $26.8M and $96.7M in 2023; R&D expense $124.5M FY.
- Cash, equivalents & marketable securities $434.1M at Dec 31, 2024, up from $250M private placement.
- Phase 3 OPERA-01 monotherapy top-line data expected 2026; OPERA-02 combo trial with Novartis starts 2025.
- Phase 1 trial of OP-3136 initiated in Q4 2024; patients currently enrolling.
- Updated mPFS data for palazestrant + ribociclib presented at March 2025 TD Cowen; mature data pending.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000095017025041186/0000950170-25-041186-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000095017025041186/olma-20250318.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-041186

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer